Suppr超能文献

肿瘤微环境:对 Myc 感到厌烦。

Tumor microenvironment: becoming sick of Myc.

机构信息

Vall d'Hebron Institute of Oncology, Psg. Vall d'Hebron 119, Edifici Mediterranea, Laboratorio 20, 08035 Barcelona, Spain.

出版信息

Cell Mol Life Sci. 2012 Mar;69(6):931-4. doi: 10.1007/s00018-011-0860-x. Epub 2011 Oct 28.

Abstract

Several years ago, we described Myc as "the oncogene from hell", since evidence had just emerged that Myc, aside from being responsible for cell-cycle progression and tumor expansion, was also able to induce genomic instability in culture, wreaking havoc in tumor cells and accelerating tumor progression (Soucek and Evan, Cancer Cell 1:406-408, 2002; Vafa et al., Mol Cell 9:1031-1044, 2002). In this review, we discuss recent publications that expand Myc's evil armory to include coordination of the crosstalk between tumor and microenvironment. Indeed, endogenous Myc, acting as a client for upstream oncogenic lesions, instructs the tumor stroma, engages a complex inflammatory response and induces angiogenesis, thus allowing the tumor to thrive. This is highly topical in light of the fact that Hanahan and Weinberg have recently redefined the hallmarks of cancer and pointed out that genomic instability and inflammation are essential for both their acquisition and development (Hanahan and Weinberg, Cell 144:646-674, 2011). Myc, it seems, is behind it all.

摘要

几年前,我们将 Myc 描述为“来自地狱的癌基因”,因为当时刚刚有证据表明,Myc 除了负责细胞周期进程和肿瘤扩张外,还能够在培养物中诱导基因组不稳定性,在肿瘤细胞中造成严重破坏并加速肿瘤进展(Soucek 和 Evan,Cancer Cell 1:406-408, 2002;Vafa 等人,Mol Cell 9:1031-1044, 2002)。在这篇综述中,我们讨论了最近的一些出版物,这些出版物扩展了 Myc 的邪恶武器库,包括协调肿瘤和微环境之间的串扰。事实上,作为上游致癌病变的客户,内源性 Myc 指导肿瘤基质,参与复杂的炎症反应并诱导血管生成,从而使肿瘤得以茁壮成长。鉴于 Hanahan 和 Weinberg 最近重新定义了癌症的标志,并指出基因组不稳定性和炎症对它们的获得和发展至关重要,这一点非常重要(Hanahan 和 Weinberg,Cell 144:646-674, 2011)。似乎 Myc 是这一切的幕后黑手。

相似文献

1
Tumor microenvironment: becoming sick of Myc.
Cell Mol Life Sci. 2012 Mar;69(6):931-4. doi: 10.1007/s00018-011-0860-x. Epub 2011 Oct 28.
2
MYC as a Multifaceted Regulator of Tumor Microenvironment Leading to Metastasis.
Int J Mol Sci. 2020 Oct 18;21(20):7710. doi: 10.3390/ijms21207710.
3
Using Flow Cytometry to Study Myc's Role in Shaping the Tumor Immune Microenvironment.
Methods Mol Biol. 2021;2318:281-295. doi: 10.1007/978-1-0716-1476-1_15.
4
The myc oncogene: MarvelouslY Complex.
Adv Cancer Res. 2002;84:81-154. doi: 10.1016/s0065-230x(02)84004-0.
5
Could MYC induction of mitochondrial biogenesis be linked to ROS production and genomic instability?
Cell Cycle. 2005 Nov;4(11):1465-6. doi: 10.4161/cc.4.11.2121. Epub 2005 Nov 23.
6
Myc's broad reach.
Genes Dev. 2008 Oct 15;22(20):2755-66. doi: 10.1101/gad.1712408.
7
MYC leads the way.
Small GTPases. 2020 Mar;11(2):86-94. doi: 10.1080/21541248.2017.1364821. Epub 2017 Nov 25.
8
Myc's secret life without Max.
Cell Cycle. 2009 Dec;8(23):3848-53. doi: 10.4161/cc.8.23.10088. Epub 2009 Dec 15.
9
Acting locally and globally: Myc's ever-expanding roles on chromatin.
Cancer Res. 2009 Oct 1;69(19):7487-90. doi: 10.1158/0008-5472.CAN-08-4832. Epub 2009 Sep 22.
10
An "-omycs" Toolbox to Work with MYC.
Methods Mol Biol. 2021;2318:1-11. doi: 10.1007/978-1-0716-1476-1_1.

引用本文的文献

3
Exploiting replication stress for synthetic lethality in MYC-driven cancers.
Am J Cancer Res. 2025 Apr 15;15(4):1461-1479. doi: 10.62347/RTVX8866. eCollection 2025.
4
Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target.
Int J Mol Sci. 2025 Feb 25;26(5):1973. doi: 10.3390/ijms26051973.
5
Advances in biomarkers for immunotherapy in small-cell lung cancer.
Front Immunol. 2024 Dec 11;15:1490590. doi: 10.3389/fimmu.2024.1490590. eCollection 2024.
7
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.
J Exp Clin Cancer Res. 2024 Nov 1;43(1):294. doi: 10.1186/s13046-024-03217-2.
8
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.
Signal Transduct Target Ther. 2024 Aug 21;9(1):205. doi: 10.1038/s41392-024-01907-z.
9
MYC: there is more to it than cancer.
Front Cell Dev Biol. 2024 Mar 6;12:1342872. doi: 10.3389/fcell.2024.1342872. eCollection 2024.
10
MYC targeting by OMO-103 in solid tumors: a phase 1 trial.
Nat Med. 2024 Mar;30(3):762-771. doi: 10.1038/s41591-024-02805-1. Epub 2024 Feb 6.

本文引用的文献

1
Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology.
Blood. 2012 Jan 12;119(2):411-21. doi: 10.1182/blood-2011-02-339911. Epub 2011 Nov 8.
2
The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy.
PLoS One. 2011;6(7):e22284. doi: 10.1371/journal.pone.0022284. Epub 2011 Jul 21.
3
Endogenous Myc maintains the tumor microenvironment.
Genes Dev. 2011 May 1;25(9):907-16. doi: 10.1101/gad.2038411. Epub 2011 Apr 8.
4
Hallmarks of cancer: the next generation.
Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
6
Downregulation of c-MYC protein levels contributes to cancer cell survival under dual deficiency of oxygen and glucose.
Cancer Res. 2010 Dec 15;70(24):10213-23. doi: 10.1158/0008-5472.CAN-10-2720. Epub 2010 Oct 27.
7
MYC in oncogenesis and as a target for cancer therapies.
Adv Cancer Res. 2010;107:163-224. doi: 10.1016/S0065-230X(10)07006-5.
8
Edgetic perturbation models of human inherited disorders.
Mol Syst Biol. 2009;5:321. doi: 10.1038/msb.2009.80. Epub 2009 Nov 3.
9
Microenvironmental regulation of metastasis.
Nat Rev Cancer. 2009 Apr;9(4):239-52. doi: 10.1038/nrc2618. Epub 2008 Mar 12.
10
Modelling Myc inhibition as a cancer therapy.
Nature. 2008 Oct 2;455(7213):679-83. doi: 10.1038/nature07260. Epub 2008 Aug 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验